|Bid||60.00 x 100|
|Ask||75.22 x 200|
|Day's Range||69.68 - 70.19|
|52 Week Range||56.59 - 73.46|
|PE Ratio (TTM)||30.73|
|Earnings Date||Jul 26, 2017 - Jul 31, 2017|
|Dividend & Yield||1.32 (1.88%)|
|1y Target Est||66.56|
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ResMed, Inc. Here are 5 ETFs with the largest exposure to RMD-US. Comparing the performance and risk of ResMed, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
WASHINGTON, May 22, 2017 /PRNewswire/ -- According to a new ResMed-sponsored (NYSE:RMD) study, people with treatment-emergent central sleep apnea (CSA) have a significantly greater risk of terminating ...
WASHINGTON, May 21, 2017 /PRNewswire/ -- People suffering from chronic obstructive pulmonary disease (COPD) – the third leading cause of death in the United States – may see their lives change thanks to a ResMed-sponsored clinical trial (RMD) presented at the 2017 American Thoracic Society International Conference and published in the Journal of the American Medical Association (JAMA) today. The trial, Home Oxygen Therapy - Home Mechanical Ventilation (HOT-HMV), was designed to investigate the effect of using non-invasive ventilation (NIV) at home on time to hospital readmission or death. Patients in the study had persistent hypercapnia (high levels of carbon dioxide in their blood) and had recently been hospitalized for a worsening of their COPD.